The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone

Pain Physician

Volumn 16, Issue 3, 2013, Pages

  Boswell, Mark V ^a   Elaine Stauble, M ^a   Loyd, Gary E ^a   Langman, Loralie ^b   Ramey Hartung, Bronwyn ^c   Baumgartner, Richard N ^d   Tucker, William W ^a   Jortani, Saeed A ^a  

^a University of Louisville School of Medicine   (United States)

^b MAYO CLINIC   (United States)

^c PGXL Laboratories   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Cesarean section; Female gender; Genetic polymorphisms; Hydrocodone; Hydromorphone; Opioid concentrations; Opioid Mu; OPRM1; Postoperative pain; Receptor; Rs1799971; Serum

Indexed keywords

ANALGESIC AGENT; BUPIVACAINE; CODEINE; HYDROCODONE; HYDROCODONE PLUS PARACETAMOL; HYDROMORPHONE; IBUPROFEN; MORPHINE; MORPHINE SULFATE; MU 1 OPIATE RECEPTOR; MU OPIATE RECEPTOR; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANALGESIA; ANOREXIA; ARTICLE; BODY MASS; CESAREAN SECTION; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; NAUSEA; PAIN ASSESSMENT; PHARMACOGENETICS; POSTOPERATIVE CARE; POSTOPERATIVE PAIN; PROSPECTIVE STUDY; PRURITUS; RESPIRATION DEPRESSION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; SOMNOLENCE; SPINAL ANESTHESIA; SWEATING; TANDEM MASS SPECTROMETRY; VENOUS BLOOD; VISUAL ANALOG SCALE; VOMITING; WEAKNESS; XEROSTOMIA;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHROMATOGRAPHY, LIQUID; FEMALE; GENOTYPE; HUMANS; HYDROCODONE; HYDROMORPHONE; MIDDLE AGED; OBSTETRIC SURGICAL PROCEDURES; PAIN, POSTOPERATIVE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84878219340     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48:1232-1239.
2. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105:334-337.
3. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006; 50:787-792.
4. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83:559-566.
5. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, Teo YY, Tan EC. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008; 109:520-526.
6. De Capraris A, Cinnella G, Marolla A, Salatto P, Da Lima S, Vetuschi P, Consoletti L, Gesualdo L, Dambrosio M. Micro opioid receptor A118G polymorphism and post-operative pain: Opioids' effects on heterozygous patients. Int J Immunopathol Pharmacol 2011; 24:993-1004.
7. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol 2011; 77:33-39.
8. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16:625-636.
9. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146:270-275.
10. Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M, Lundström S, Maltoni M, Radbruch L, Sabatowski R, Sigurdardottir V, Strasser F, Fayers PM, Kaasa S. Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients. Pain 2011; 152:1139-1145.
11. Cone EJ, Darwin WD, Gorodetzky CW, Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 1978; 6:488-493.
12. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54:463-472.
13. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O-and N-demethylated metabolites at mu-and delta-opioid receptors. J Pharmacol Exp Ther 2004; 308:547-554.
14. Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, Kropp TJ, Verbois SL. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011; 59:385-390.
15. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48:2165-2171.
16. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280:32618-32624.
17. Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, Schmidt PH, Lotsch J. A common human microopioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 2009; 284:6530-6535.
18. Mahmoud S, Thorsell A, Sommer WH, Heilig M, Holgate JK, Bartlett SE, Ruiz-Velasco V. Pharmacological consequence of the A118G mu opioid receptor polymorphism on morphine-and fentanylmediated modulation of Ca(2) channels in humanized mouse sensory neurons. Anesthesiology 2011; 115:1054-1062.
19. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A 2011; 108:9268-9273.
20. Kroslak T, LaForge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103:77-87.
21. Pasternak GW. Preclinical pharmacology and opioid combinations. Pain Med 2012; 13 Suppl 1:S4-S11.